Ara Chackerian Brings TMS Therapy to the World

Ara Chackerian wears a lot of professional hats. Currently, he is the Managing Director of ASC Capital Holdings, LLC. He also finds time to be an angel investor, entrepreneur, and philanthropist. His company invests in healthcare companies that are in the early stages of growth. He has more than 20 years of experience with bringing healthcare companies up to a level of profitability and sustainability.

On the entrepreneurial side of things, Chackerian has helped co-found several companies while working as the CEO of others. One of the areas of medical science that he is actively involved in is Transcranial Magnetic Stimulation. TMS offers a high-tech approach to treating health disorders that are behavioral in nature.

TMS, for more than ten years, is one method used to help patients suffering from chronic depression. Some patients do not respond to medication and the usual approaches medical practitioners use in behavioral healthcare. The TMS process reduces 50-60 percent of the symptoms in patients undergoing treatment for chronic depression. This is usually the effect of TMS when used in conjunction with traditional therapies. Check out for more.

Ara Chackerian, an early backer of TMS, believes it holds an enormous amount of potential for patients. Patients suffering from chronic depression experience debilitating effects, and often have great difficulties navigating life. TMS can include treatments for bipolar disorder, post-traumatic stress, and other related mental illnesses. Perhaps the greatest benefit to patients is there are no harmful side effects. The treatment, performed in a clinical environment, is pain-free. Patients are free to drive home after their treatment.

As the fonder of TMS Health Solutions, Chackerian also helped create the company’s insurance policies behind TMS therapy. Ara Chackerian continues to distinguish himself in his field and to set standards for anyone looking to pursue success. For patients suffering from depression, there is hope for a solution.

Click here:

Scott Rocklage Excels in Disease Research

Mytonis Dystrophy type 1 a genetic disorder that deteriorates muscles and organs until they no longer function. The disease affects about 1 in 8,000 people in the world and typically appears between the age of 20 and 30. The disorder is commonly referred to as Steinert disease. Learn more:


Scott Rocklage and his organization, Expansion Therapeutics, have been attempting to find cures and therapies for patients with DS1. In 2018 the company announced that it had raised an additional 55 million dollars to help fund the way to helping patients.


The rare disease occurs when fragments of DNA repeat themselves in an individual. These cloned sequence of DNA are the cause of RNA increase, which in turn, due to its toxic properties in high levels begin the muscle deterioration. Rocklage and Company are working to create medicines that attack the RNA and put a stop on the damage that mytonis dystrophy has caused. There is no known cure at the moment, but everyone at Expansion Therapeutics are excited to adventure into the unknown and possibly provide relief for thousands of hurting patients.


About Scott Rocklage


Scott Rocklage was a student at the University of California, MIT, and Berkeley and is now a Managing Partner at 5AM Ventures. Rocklage joined the company in 2003 and in just two years he was awarded the Nobel Peace Prize in Chemistry.


Before joining 5AM Ventures Rocklage spent two decades with other companies producing new FDA approved medicines. He has worked with companies such as Cubist Pharmaceuticals, Nycomed Salutar, Relppsa, and Achaogen. Scott Rocklage currently resides in Boston, Massachusetts